Roflumilast
Brand names: Zoryve, Daliresp, Roflumilast
At a glance
- Medicare prescriptions, 2024
- 265,698
- Medicare drug cost
- $32.1M
- Average cost per prescription
- $121
- Clinicians who prescribed it
- 8,559
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
ZORYVE cream is a phosphodiesterase 4 inhibitor: Plaque Psoriasis ZORYVE cream, 0.3%, is indicated for the topical treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 2 years of age and older.
From the FDA-approved prescribing information (label dated July 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Pulmonology 45.6%
- Nurse Practitioners 19.5%
- Family Medicine 9.5%
- Internal Medicine 9.2%
- Physician Assistants 5.9%
- Critical Care Medicine 5.0%
- Dermatology 2.1%
- Sleep Medicine 0.7%
- Geriatric Medicine 0.6%
- General Practice 0.4%
- Hospitalist 0.4%
- Allergy & Immunology 0.2%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 5% from 2019 to 2024.
Biggest change by state since 2019
- Massachusetts +33%
- Indiana +23%
- New York +22%
- Florida +18%
- Georgia +17%
- West Virginia (smallest change) −14%
- South Carolina (smallest change) −11%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 4 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Amici Pharma Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 250 ug | yellow round tablet, 5 mm | A116 |
| 500 ug | white round tablet, 5 mm | A117 |
Arcutis Biotherapeutics, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 0.5 mg | white cream | |
| 1.5 mg | white cream | |
| 3 mg | white cream | |
Avkare
| Strength | Looks like | Imprint |
|---|---|---|
| 250 ug | white round tablet, 5 mm | 4 C |
| 500 ug | white round tablet, 5 mm | 05 R |
Jubilant Cadista Pharmaceuticals Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 250 ug | yellow round tablet, 5 mm | A 116 |
| 500 ug | white round tablet, 5 mm | A 117 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $8.2M in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Arcutis Biotherapeutics, Inc. $7.2M
- Kowa Pharmaceuticals America, Inc. $1.0M
- AstraZeneca Pharmaceuticals LP $2,630
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.